Active Ingredient History

  • Now
Omigapil is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit, but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD).   Wikipedia

  • SMILES: CN(CC#C)CC1=Cc2ccccc2Oc3ccccc13
  • Mol. Mass: 275.35
  • ALogP: 3.9
  • ChEMBL Molecule:
More Chemistry
cgp 3466 | cgp-3466 | cgp3466b | cgp 3466b | cgp-3466b | dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine | omigapil | tch346 | tch 346 | tch-346


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue